NASDAQ:OKUR OnKure Therapeutics Q3 2024 Earnings Report $3.56 +0.02 (+0.56%) As of 09/3/2026 04:00 PM Eastern ProfileEarnings HistoryForecast OnKure Therapeutics EPS ResultsActual EPS-$1.10Consensus EPS -$0.97Beat/MissMissed by -$0.13One Year Ago EPSN/AOnKure Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOnKure Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsOnKure Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile OnKure Therapeutics Earnings HeadlinesOnKure Therapeutics (NASDAQ:OKUR) Shares Up 0.6% - What's Next?53 minutes ago | americanbankingnews.comOnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare ConferenceAugust 31, 2026 | globenewswire.comMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now. | TradeSmith (Ad)OnKure Therapeutics Inc. - Ordinary Shares - Class AAugust 19, 2026 | money.usnews.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)August 6, 2026 | theglobeandmail.comOnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsAugust 4, 2026 | globenewswire.comSee More OnKure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email. Email Address About OnKure TherapeuticsOnKure Therapeutics (NASDAQ:OKUR) (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function. The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors. OKI-179 is designed to achieve potent antitumor activity while minimizing the off-target toxicities associated with earlier HDAC inhibitors. In parallel, OnKure is developing OKI-272, a reversible Bruton’s tyrosine kinase (BTK) inhibitor targeting B-cell malignancies and autoimmune conditions, with ongoing preclinical and early clinical assessments. Founded by a team experienced in drug discovery and clinical development, OnKure leverages integrated chemistry, biology, and translational science capabilities to move its pipeline forward. The company collaborates with specialized contract research organizations and academic centers to support its clinical programs and accelerate development timelines. OnKure’s management team brings together industry veterans with extensive backgrounds in oncology drug development, clinical operations, and regulatory affairs. The company is committed to advancing its therapeutic candidates through clinical proof-of-concept and toward potential commercialization for patients with high unmet medical needs.View OnKure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth StoryPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation Test Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
